Expanding Indications into Dermatology & Metabolic Disorders to Address Unmet Needs

• Presenting preclinical data on a dual-strain LBP for atopic dermatitis that restores skin barrier function and reduces S. aureus colonisation
• Optimising topical formulation strategies and translational plans for dermatology applications in both human and veterinary models
• Introducing a microbiome-based co-therapy to mitigate GLP-1 side effects in obesity treatment while preserving gut barrier integrity

Speakers:

Yongkyu Kim

Chief Executive Officer

Biomatz